ClinicalTrials.gg
RecruitingNCT06300320Updated Aug 26, 2026

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

A Phase 2 interventional study of TQ05105 tablets in Chronic Graft Versus Host Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Planned enrollment
17th of 42
65 · median 50
Started
2024
with 4 others
Phase 2
14 of 52
6 open now
Primary completion
2027-11
later than 13 of 24 live
Registered
32nd of 52
by date
Lead sponsor
2 of 52
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 17th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2024, is one of 14 in phase 2, reaches primary completion later than 13 of the 24 other live ones, and was the 32nd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease

03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary and signed , good compliance;
  • Age 18-70 years old; Performance Scale (KPS) ≥60 points; ≥ 6months.
  • Received hematopoietic stem cell transplantation;
  • Diagnosis of moderate-to-severe chronic (cGVHD)
  • Received systemic therapies for cGVHD;
  • Stable dose of , other therapy received within 2 weeks prior to screening;
  • (ANC) ≥ 1.0×10 9/L ; count (PLT) ≥30×10 9 /L; ≥80g/L; There were no obvious abnormalities in liver and kidney function and coagulation function;
  • Men and women of childbearing age agree to use measures during the study period and within 6 months after the end of the study

Exclusion criteria

Exclusion Criteria:

  • Currently present or occured other within 3 years prior to first administration;
  • Known or suspected active acute (aGVHD);
  • Presence of infection requiring treatment within 7 days prior to randomization;
  • Failed hematopoietic stem cell transplantation within 6 months or 2 prior allogeneic hematopoietic stem cell transplants;
  • Use of Janus-activated kinase (JAK) inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, or other, chemotherapeutic agents within 2 weeks prior to randomization;
  • Has a variety of factors that affect oral medications (e.g., inability to swallow, , intestinal obstruction, etc;
  • Those who have a history of psychotropic drug abuse and cannot be abstained from or have a mental disorder;
  • Have any severe or uncontrolled serious illness, including but not limited to uncontrolled hypertension, heart disease, hepatitis and epilepsy that require treatment;
  • Have any severe or uncontrolled serious illness, including but not limited to,uncontrolled hypertension heart disease, hepatitis and epilepsy that require treatment;
  • Those who are allergic to the study drug or its components;
  • Participation in other clinical trials or major surgery within 4 weeks prior to the first dose;
  • Subjects judged by the investigator to be unsuitable for enrollment;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    TQ05105 Tablets

    TQ05105 Tablets administered twice-daily. 28 days as a treatment cycle.

    Drug: TQ05105 tablets

Interventions

  • Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) at 24 weeks

    Percentage of subjects with an overall response of all evaluable organs as complete response (CR) or partial response (PR).

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Best objective response rate (BOR)

    Proportion of subjects achieving CR+PR and at any time point prior to initiation of other systemic therapies for cGVHD

    Time frame: Up to 96 weeks

  2. Duration of response (DOR)

    Time to first response to cGVHD disease progression, death, or initiation of any new systemic therapy for cGVHD

    Time frame: Up to 96 weeks

  3. Failure-free survival (FFS)

    The time from the first dose to the time of recurrence, death, or death or increase in non-original disease or initiation of a new cGVHD systemic

    Time frame: Up to 96 weeks

  4. Incidence rate of malignancy relapse or recurrence

    Proportion of subjects with recurrence date of blood system disease from the first dose

    Time frame: Up to 96 weeks

  5. Non relapse mortality

    From first dose to the date of death, with no recurrence of the original disease

    Time frame: At least 96 weeks

  6. Overall Survival (OS)

    Time from first dose to death caused by various reasons

    Time frame: At least 96 weeks

  7. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) , evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Up to 96 weeks

  8. Severity of adverse events (AEs)

    Severity of all adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Up to 48 weeks

07

Study locations

1 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2027, 42 months after the start.

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 8, 2024
StartActual
May 7, 2024
Primary completionEst.
Nov 2027
CompletionEst.
May 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06300320
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
May 7, 2024
Primary completion
Nov 2027 (estimated)
Completion
May 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

He Huang, PhD
Contact
hehuangyu@126.com
13605714822

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion